- Home
- DXR vs ADVB Comparison
DXR vs ADVB Comparison
Compare DXR & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- ADVB
- Stock Information
- Founded
- DXR 1970
- ADVB 2014
- Country
- DXR United States
- ADVB United States
- Employees
- DXR N/A
- ADVB N/A
- Industry
- DXR Medical/Dental Instruments
- ADVB Medical Specialities
- Sector
- DXR Health Care
- ADVB Health Care
- Exchange
- DXR Nasdaq
- ADVB Nasdaq
- Market Cap
- DXR 36.4M
- ADVB 36.1M
- IPO Year
- DXR N/A
- ADVB 2025
- Fundamental
- Price
- DXR $9.25
- ADVB $0.94
- Analyst Decision
- DXR Strong Buy
- ADVB
- Analyst Count
- DXR 1
- ADVB 0
- Target Price
- DXR $25.00
- ADVB N/A
- AVG Volume (30 Days)
- DXR 2.8K
- ADVB 72.3K
- Earning Date
- DXR 01-01-0001
- ADVB 08-03-2025
- Dividend Yield
- DXR N/A
- ADVB N/A
- EPS Growth
- DXR 86.16
- ADVB N/A
- EPS
- DXR 0.11
- ADVB N/A
- Revenue
- DXR $119,714.00
- ADVB N/A
- Revenue This Year
- DXR N/A
- ADVB N/A
- Revenue Next Year
- DXR N/A
- ADVB N/A
- P/E Ratio
- DXR $81.69
- ADVB N/A
- Revenue Growth
- DXR N/A
- ADVB N/A
- 52 Week Low
- DXR $6.55
- ADVB $0.86
- 52 Week High
- DXR $10.00
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- DXR 73.43
- ADVB N/A
- Support Level
- DXR $8.29
- ADVB N/A
- Resistance Level
- DXR $8.13
- ADVB N/A
- Average True Range (ATR)
- DXR 0.32
- ADVB 0.00
- MACD
- DXR 0.14
- ADVB 0.00
- Stochastic Oscillator
- DXR 100.00
- ADVB 0.00
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.